Profile
CHRO VRTX REGN VRNA ARGX ALNY
Company Name Channel Therapeutics Corporation Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $8.90M $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.00K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Francis Knuettel II, Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
CHRO VRTX REGN VRNA ARGX ALNY
Quant Rating Score 2 4 4 1 4 3
Quant Rating Sell Buy Buy Strong Sell Buy Neutral
Trading
CHRO VRTX REGN VRNA ARGX ALNY
Last Close $1.35 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $2.79 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.54 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -51.61 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 150 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
CHRO VRTX REGN VRNA ARGX ALNY
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return 0 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 35 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return -24.16 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 110.61 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 149.54 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CHRO VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
CHRO VRTX REGN VRNA ARGX ALNY
Asset Growth 1320.41 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth 100 % 1.16 % - 26.81 %
Revenue Growth - 0.99 % - 22.97 %
Revenue 3 Year - 20.64 % -15.89 % 147.1 %
Revenue 5 Year -100 % 73.64 % - 775.72 %
Revenue 10 Year -100 % 285.02 % - 2487.4 %
EBIT Growth -27.39 % 9.09 % -131.37 % 24.59 %
Net Income Growth -7.78 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share -1282.44 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share -1145.99 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share -1145.99 % 680.22 % -35.51 % 55.09 %
Operating Income Growth -10.33 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) -490.45 % - -143.33 % -107.98 %
Operating 3 Year CFG -276.21 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG -65.29 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG -65.29 % -100 % 40.15 % 97.08 %
EPS Growth -11.72 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth -11.72 % 8.19 % -208.93 % 38.07 %
Book Value Per Share 56.43 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share 23.7 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share 21.52 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share 21.52 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth 72.31 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth -490.45 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
CHRO VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM 3.27 % 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -18.65 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -210.32 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -6.78 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 98.07 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 349.03 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM -82.61 % 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -596.99 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM 1.04 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM 0.19 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM 0.05 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM 58.91 % 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM 6.6 % 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -5.56 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -5.56 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 463.92 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM -203.95 % 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -596.99 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -0.52 36.72 20 -995.27 127.92 195.85
Price To Operating Cash Flows Ratio TTM -0.24 32.86 16.23 -126.33 144.41 162.25
Price Cash Flow Ratio TTM -0.24 32.86 16.23 -126.33 144.41 162.25
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.6
AARD Aardvark Therapeutics, Inc. Common Stock 12.67
ABCL AbCellera Biologics Inc. 3.135
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.06
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.56
ABPWW 0.0133
ABSI Absci Corporation 2.6
ABUS Arbutus Biopharma Corporation 4.16
ABVC ABVC BioPharma, Inc. 1.73
ABVX Abivax SA American Depositary Shares 122.77
ACAD ACADIA Pharmaceuticals Inc. 22.47
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 6.81
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.28
ACIU AC Immune SA 3.03
Unlock